DOI
10.1200/JCO.20.01616
How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies
Authors
Patrick M. Reagan
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Patrick M. Reagan, Sattva S. Neelapu
Preview
Journal Details
Published Date
January 12, 2021
Similar Journals
Journal
Journal of Clinical Oncology
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
First Author: Navin Pinto
Publish Date: Sep 10, 2024
Journal
JCO Oncology Practice
Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
First Author: Rosalyn I. Marar
Publish Date: Mar 17, 2023
Journal
Journal of Clinical Oncology
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
First Author: Nirali N. Shah
Publish Date: Apr 1, 2020
Journal
Journal of Clinical Oncology
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
First Author: Jennifer N. Brudno
Publish Date: May 29, 2018